XML 33 R22.htm IDEA: XBRL DOCUMENT v3.7.0.1
Intangible Assets
 6 Months Ended
Apr. 01, 2017
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible Assets
Intangible Assets
Intangible assets consisted of the following:
 
Description
As of April 1, 2017
 
As of September 24, 2016
Gross
Carrying
Value
 
Accumulated
Amortization
 
Gross
Carrying
Value
 
Accumulated
Amortization
Developed technology
$
4,463.4

 
$
2,028.2

 
$
3,983.7

 
$
1,991.6

In-process research and development
110.7

 
—

 
3.7

 
—

Customer relationships
547.4

 
374.7

 
1,098.9

 
546.2

Trade names
310.2

 
146.9

 
236.2

 
141.6

Distribution agreement
42.0

 
0.3

 
—

 
—

Business licenses
2.4

 
2.1

 
2.4

 
2.1

 
$
5,476.1


$
2,552.2


$
5,324.9


$
2,681.5


During the second quarter, the Company divested its blood screening business and as such $154.0 million of net book value of developed technology and $387.7 million of net book value of customer contract assets were disposed of. In addition, in the second quarter of fiscal 2017, the Company acquired Cynosure and recorded an aggregate of $994.0 million of intangible assets (see Note 3).
The estimated remaining amortization expense as of April 1, 2017 for each of the five succeeding fiscal years is as follows:
Remainder of Fiscal 2017
$
188.2

Fiscal 2018
$
369.0

Fiscal 2019
$
357.2

Fiscal 2020
$
346.1

Fiscal 2021
$
324.7